CSD210904: Study to Assess Actual Use of a Heated Tobacco Product With Four Non-Combusted Cigarette Variants in Current Adult Smokers

Smoking Clinical Trial

Official title:

A Multi-Site Study to Assess Actual Use of a Heated Tobacco Product With Four Non-Combusted Cigarette Variants in Current Adult Smokers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05102786
• Other study ID #: CSD210904
• Status: Completed
• Start date: October 26, 2021
• Est. completion date: March 8, 2022

Study information

• Verified date: June 2022
• Source: RAI Services Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a multi-site, open-label, 8-week, prospective observational study, conducted at multiple sites geographically dispersed within the U.S. The purpose of this Actual Use Study (AUS) is to investigate how U.S. adult tobacco consumers 21 to 60 years of age, inclusive, who typically smoke on average (≥5 cigarettes/day) on at least 20 out of the past 30 days will use a heated tobacco product comprising a heating device and four non-combusted cigarette variants (HTP Investigational Product [IP]) over a 6-week Actual Use Period (AUP) in their real-life/naturalistic environment and in the context of typical consumer marketing materials.

Description:

Adult smokers will be recruited, and candidate subjects who meet study inclusion criteria and none of the exclusion criteria will give verbal consent for further screening. Candidate subjects will be scheduled to attend an in-person Site Enrollment Visit. Subjects will self-report their ad libitum use of the HTP IP as well as use of combustible cigarettes (CCs) and any other tobacco- or nicotine-containing products (TNPs) on a daily basis using an electronic diary (eDiary).

During a 1-week Baseline Assessment Period (BAP), enrolled subjects will record all CC and any other TNP use in the eDiary. At the end of the BAP, subjects will return to the study site for Site Visit 1 (SV1). At this visit, subjects will be provided the HTP IP for the first two weeks of the AUP.

During the subsequent 6-week observational AUP, subjects can choose to use the HTP IP (or not). Subjects will be instructed to record all daily TNP and CC use in the eDiary. They will return to the site every two weeks during the AUP for an in-person interview, to complete questionnaires and for product accountability and resupply. As with SV1, at Site Visit 2 and 3, subjects will be able to select their preferred HTP IP variants (if desired) for use during the subsequent 2-week AUP. Point of sale materials will be present during subject interactions at SVs. After Week 6 of the AUP, there will be a final site visit and week-long Close Out Period.

In addition to collecting information on daily ad libitum use of HTP IP, TNP and CC use, the study will assess subjective measures for each HTP IP, including product use/misuse and intent to use again (at close of study). Information on intention to quit CC use will be collected at enrollment and at study conclusion. A passive surveillance mechanism will be used to collect information on adverse health experiences.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1180
• Est. completion date: March 8, 2022
• Est. primary completion date: March 8, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Adult males or females, 21-60 years old, inclusive, verified with government-issued photo ID.

2. Must be a current smoker of factory-made filtered menthol and/or non-menthol cigarettes, has smoked at least 100 cigarettes in their lifetime, and typically smoke on at least 20 days out of the past 30 days.

3. Smokes, on average, = 5 combustible cigarettes per day (CPD) on days when cigarettes are smoked.

4. Must indicate "an intention to use" the HTP IP after a brief review of product information at the Screening and Enrollment Visit (SEV). Subjects will not try the product at the SEV.

5. Available and interested in participating in an 8-week study about the HTP IP.

6. Able and willing to comply with all study requirements, including questionnaires, the eDiary reporting procedures, and provide valid contact information.

7. Able to read, understand, and willing to sign Informed Consent Forms (ICFs) and complete questionnaires written in English.

8. Has not participated in any tobacco-, vapor-, or nicotine-related research within 3 months of screening.

Exclusion Criteria:

1. Self-reports as currently quitting or intending to quit within the next 3 months all tobacco or nicotine product use ("currently" is defined as within (=) 30 days prior to signing ICF#1). Those who intend to quit CC only can be enrolled.

2. Female subjects who are currently pregnant or breastfeeding or planning to become pregnant or start breastfeeding within the next 6 months based on self-report.

3. Female subjects who self-report they are not using adequate methods to prevent pregnancy.

4. Self-reports "poor" physical health (based on the five-category Population Assessment of Tobacco and Health (PATH) questionnaire): "In general, how would you rate your physical health?" (Response choices: Excellent, Very Good, Good, Fair, Poor).

5. Self-reports "poor" mental health (based on the five-category PATH questionnaire): "In general, how would you rate your mental health?" (Response choices: Excellent, Very Good, Good, Fair, Poor).

6. Employees of tobacco or vapor companies.

Related Conditions & MeSH terms

• Smoking
• Tobacco Smoking
• Tobacco Use

Intervention

Other:
• 40007388
A non-combusted cigarette used with heated tobacco device 20020064
• 40007385
A non-combusted cigarette used with heated tobacco device 20020064
• 40007387
A non-combusted cigarette used with heated tobacco device 20020064
• 40007386
A non-combusted cigarette used with heated tobacco device 20020064

Locations

Country	Name	City	State
United States	Schlesinger Atlanta	Atlanta	Georgia
United States	Schlesinger Baltimore	Baltimore	Maryland
United States	Schlesinger Charlotte	Charlotte	North Carolina
United States	Schlesinger Chicago	Chicago	Illinois
United States	Schlesinger Dallas	Dallas	Texas
United States	Schlesinger Minneapolis	Edina	Minnesota
United States	Schlesinger Houston	Houston	Texas
United States	Schlesinger Kansas City	Kansas City	Missouri
United States	Schlesinger Nashville	Nashville	Tennessee
United States	Schlesinger St. Louis	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
RAI Services Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number and Proportion of Established Users	Number and proportion of subjects who meet the definition of "established users" of the HTP IP	6 weeks
Primary	Number and Proportion of Established Users who reduce their CPD consumption	Number and proportion of subjects among "established users" of the HTP IP who reduce their CPD consumption by at least 50%	8 weeks
Primary	Descriptive weekly average CPD consumption	Descriptive weekly average CPD consumption per subject among all subjects who complete the study, including both established and non-established users of the HTP IP	8 weeks